Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Expert Rev Gastroenterol Hepatol. 2013 May;7(4):365-85. doi: 10.1586/egh.13.21.
Autoimmune hepatitis has diverse clinical phenotypes and outcomes in ethnic groups within a country and between countries, and these differences may reflect genetic predispositions, indigenous etiological agents, pharmacogenomic mechanisms and socioeconomic reasons. In the USA, African-American patients have cirrhosis more commonly, treatment failure more frequently and higher mortality than white American patients. Survival is poorest in Asian-American patients. Autoimmune hepatitis in other countries is frequently associated with genetic predispositions that may favor susceptibility to indigenous etiological agents. Cholestatic features influence treatment response; acute-on-chronic liver disease increases mortality and socioeconomic and cultural factors affect prognosis. Ethnic-based deviations from classical phenotypes and the frequency of late-stage disease can complicate the diagnosis and management of autoimmune hepatitis in non-white populations.
自身免疫性肝炎在一个国家内的不同种族群体以及不同国家之间具有不同的临床表型和结局,这些差异可能反映了遗传易感性、本地病因、药物基因组学机制和社会经济原因。在美国,非裔美国患者比白种美国患者更常见肝硬化、治疗失败和更高的死亡率。亚洲裔美国患者的生存率最差。其他国家的自身免疫性肝炎常与遗传易感性相关,可能易受本地病因的影响。胆汁淤积特征影响治疗反应;慢加急性肝衰竭增加死亡率,社会经济和文化因素影响预后。非白人人群中,基于种族的偏离经典表型和晚期疾病的频率可能使自身免疫性肝炎的诊断和管理复杂化。